Effect of timing of administration on lipid-lowering efficacy of statins-meta-analysis

被引:0
作者
Wang, Chang [1 ]
Quan, Yawen [2 ]
Wang, Linfeng [3 ]
Li, Gang [1 ,4 ]
机构
[1] North China Univ Sci & Technol, Grad Sch, Tangshan, Hebei, Peoples R China
[2] Hebei Med Univ, Grad Sch, Shijiazhuang, Hebei, Peoples R China
[3] Hebei North Univ, Grad Sch, Zhangjiakou, Hebei, Peoples R China
[4] Hebei Gen Hosp, Inst Geriatr Dis, Div Cardiol, Shijiazhuang 050000, Hebei, Peoples R China
基金
中国国家自然科学基金;
关键词
Statins; Low-density lipoprotein cholesterol; Cholesterol; Half-life; Duration of medication; Medication morning and evening; CONTROLLED-RELEASE SIMVASTATIN; OPTICAL COHERENCE TOMOGRAPHY; ACUTE MYOCARDIAL-INFARCTION; SERUM-CHOLESTEROL; EVENING INTAKE; DOUBLE-BLIND; SAFETY; ATORVASTATIN; RATIONALE; THERAPY;
D O I
10.1007/s00228-023-03575-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background To investigate the effect of timing of statin administration on lipid-lowering efficacy.Methods Computer searches of Pubmed, Embase, Cochrane Library, and Web of Science databases from 1986 to 2023. The impact of administration time on the lipid-lowering efficacy of statin drugs was investigated. Following a series of screenings, a funnel plot was constructed to assess its symmetry, and Egger and Beggar tests were conducted using StataMP-64 to evaluate publication bias. Meta-analysis was performed using RevMan 5.3 to combine MD values.Results Fifteen papers (1352 participants) met and included the criteria. The results of the meta-analysis showed that the effect of morning and evening administration time on plasma triglycerides (TG) (P > 0.05) and plasma high-density lipoprotein cholesterol (HDL-C) (P > 0.05) was not statistically significant. There were significant reductions in total cholesterol (TC) (MD: 0.15 mmol/L, 95% CI: 0.06-0.23, P < 0.01) and low-density lipoprotein cholesterol (LDL-C) (MD: 0.10 mmol/L, 95% CI: - 0.00-0.20, P < 0.01) in the night group. According to the analysis results of the half-life of statins, only short half-life statins showed that nocturnal administration reduced LDL-C (MD: 0.21 mmol/L, 95% CI: 0.09-0.33, P < 0.01) and TC (MD: 0.32 mmol/L, 95% CI: 0.18-0.46, P < 0.01) levels and was better than morning administration. Long half-life statins did not show significant differences. In addition, the administration time of short half-life statins also showed that night administration tended to reduce TG (MD: 0.16 mmol/L, 95% CI: 0.02-0.30, P < 0.05) levels. In subgroup analysis according to clinical factors in patients aged < 55 years, there was no significant difference in the timing of administration between the two groups; the efficacy of statins in lowering lipids in patients aged >= 55 years was significantly different in the TC group (P < 0.01) and LDL-C group (P < 0.01). The administration time of the TC group (P < 0.05) and LDL-C group (P < 0.05) in the Americas, Europe, and Asian groups was significantly different for statins. In addition, the American group also showed that the administration time of the two groups was significantly different from the TG group (P < 0.05).Conclusion The efficacy of administering short half-life statin drugs at night in reducing plasma levels of TC, LDL-C, and TG surpasses that of morning administration. However, this study did not determine the impact of timing of statin administration in patients taking long half-life statins on the efficacy of the medication. Therefore, it is recommended to consider patient adherence when. The study was registered on PROSPERO (International Prospective Register of Systematic Reviews) as CRD42022372105 (available at https://www.crd.york.ac.uk/prospero/).
引用
收藏
页码:1641 / 1656
页数:16
相关论文
共 50 条
  • [41] Pharmacogenomics of lipid-lowering agents: the impact on efficacy and safety
    Shatnawi, Aymen
    Kamran, Zourayz
    Al-Share, Qusai
    PERSONALIZED MEDICINE, 2023, 20 (01) : 65 - 85
  • [42] Frequency of Common Variants in Genes Involved in Lipid-Lowering Response to Statins in Chilean Subjects with Hypercholesterolemia
    Rosales, Alexy
    Pacheco, Alejandro
    Cuevas, Alejandro
    Saavedra, Nicolas
    Zambrano, Tomas
    Lanas, Fernando
    Salazar, Luis A.
    INTERNATIONAL JOURNAL OF MORPHOLOGY, 2011, 29 (04): : 1296 - 1302
  • [43] Lipid-lowering efficacy and safety of Monascus biopigment beverage
    Reginio Jr, F. C.
    Hurtada, W. A.
    Estacio, M. A. C.
    Dizon, E., I
    INTERNATIONAL FOOD RESEARCH JOURNAL, 2017, 24 (02): : 664 - 671
  • [44] Lipid-lowering activity of artichoke extracts: A systematic review and meta-analysis
    Sahebkar, Amirhossein
    Pirro, Matteo
    Banach, Maciej
    Mikhailidis, Dimitri P.
    Atkin, Stephen L.
    Cicero, Arrigo F. G.
    CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION, 2018, 58 (15) : 2549 - 2556
  • [45] Meta-Analysis of Intensive Lipid-Lowering Therapy in Patients With Polyvascular Disease
    Alkhalil, Mohammad
    Kuzemczak, Michal
    Whitehead, Nicholas
    Kavvouras, Charalampos
    Dzavik, Vladimir
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2021, 10 (05): : 1 - 10
  • [46] ESC position paper on statins adherence and implementation of new lipid-lowering medications: barriers to be overcome
    Drexel, Heinz
    Coats, Andrew J. S.
    Spoletini, Ilaria
    Bilato, Claudio
    Mollace, Vincenzo
    Filardi, Pasquale Perrone
    Rosano, Giuseppe M. C.
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2020, 6 (02) : 115 - 121
  • [47] Differences Between Rosuvastatin and Atorvastatin in Lipid-Lowering Action and Effect on Glucose Metabolism in Japanese Hypercholesterolemic Patients With Concurrent Diabetes - Lipid-Lowering With Highly Potent Statins in Hyperlipidemia With Type 2 Diabetes Patients (LISTEN) Study
    Ogawa, Hisao
    Matsui, Kunihiko
    Saito, Yoshihiko
    Sugiyama, Seigo
    Jinnouchi, Hideaki
    Sugawara, Masahiro
    Masuda, Izuru
    Mori, Hisao
    Waki, Masako
    Yoshiyama, Minoru
    Watada, Hirotaka
    CIRCULATION JOURNAL, 2014, 78 (10) : 2512 - 2515
  • [48] Effect of Lipid-Lowering Therapy on Myocardial Ischemia
    Dan Tzivoni
    Jacob Klein
    Cardiovascular Drugs and Therapy, 1998, 12 : 135 - 139
  • [49] Drug interactions in cardiology: focus on statins and their combination with other lipid-lowering drugs
    Bellosta, Stefano
    Corsini, Alberto
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2024, 20 (11-12) : 1013 - 1021
  • [50] Lipid-lowering response to statins is affected by CYP3A5 polymorphism
    Kivistö, KT
    Niemi, M
    Schaeffeler, E
    Pitkälä, K
    Tilvis, RT
    Fromm, MF
    Schwab, M
    Eichelbaum, M
    Strandberg, T
    PHARMACOGENETICS, 2004, 14 (08): : 523 - 525